News Sentiment

BCRX sentiment intelligence

BioCryst Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 10.45 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+6.2% over one week, +20.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction 6.2% Price confirming higher
Trend fit Trend active 20.1% over four weeks
Fair value 40.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 23
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 6
Investing.com 6
Sahm 3
simplywall.st 3
Moomoo 2
Quiver Quantitative 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 33
Deals and strategy 4
Earnings 4
Analyst action 3
Regulatory and legal 2
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
Moomoo Direct company coverage

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BioCryst Pharmaceuticals has announced the appointment of David W. Jenkins as its new Chief Scientific Officer. This strategic hire is expected to bolster the company's research and development initiatives. Jenkins brings a wealth of experience to the role, which will be crucial

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 12:17
Source
Moomoo
Investing.com Direct company coverage

BioCryst names David Jenkins as chief scientific officer

BioCryst Pharmaceuticals has appointed David Jenkins as its new Chief Scientific Officer, effective immediately. Jenkins, with over 20 years of experience, will lead external innovation and partnerships for rare disease therapies, signaling a strategic shift for BioCryst. The com

Tone
Positive 70/100
Event
Market update
Published
15 Jul 2026 11:17
Source
Investing.com
Stock Titan Direct company coverage

BioCryst Appoints David Jenkins as Chief Scientific Officer | BCRX Stock News

BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed David W. Jenkins, MA, PhD, as its first Chief Scientific Officer, effective immediately. Dr. Jenkins, with over 20 years of biopharmaceutical R&D experience, will lead a research team focused on external innovation, capabiliti

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 11:17
Source
Stock Titan
Quiver Quantitative Direct company coverage

BioCryst Pharmaceuticals Names David W. Jenkins Chief Scientific Officer to Lead External Innovation Strategy

BioCryst Pharmaceuticals has appointed David W. Jenkins, MA, PhD, as its new Chief Scientific Officer, a role focused on leading external innovation and partnerships to accelerate the development of rare disease therapies. Dr. Jenkins, with over 20 years of biopharmaceutical indu

Tone
Positive 75/100
Event
Market update
Published
15 Jul 2026 11:13
Source
Quiver Quantitative
Simply Wall Street Direct company coverage

BioCryst (BCRX) Stock Looks Like A Bargain After Facility Closure

BioCryst Pharmaceuticals (BCRX) stock appears undervalued despite a 40% five-year decline, trading at a P/S ratio of 2.8x compared to an industry average of 11.2x. The company's shift towards external innovation and partnerships, coupled with takeover speculation, suggests potent

Tone
Positive 66/100
Event
Market update
Published
15 Jul 2026 01:10
Source
Simply Wall Street
GuruFocus Direct company coverage

BioCryst (BCRX) Coverage Resumed by JPMorgan with Neutral Rating

JPMorgan has resumed coverage of BioCryst Pharmaceuticals, Inc. (BCRX) with a Neutral rating and a $12 price target, noting that significant appreciation hinges on the successful launch of navenibart. The company holds a GF Score of 66/100, indicating moderate potential for long-

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 10:39
Source
GuruFocus
Investing.com Canada Direct company coverage

JPMorgan resumes BioCryst Pharma stock coverage with neutral rating By Investing.com

JPMorgan has resumed coverage of BioCryst Pharma (NASDAQ:BCRX) with a Neutral rating and a $12.00 price target for December 2027. The firm's outlook is based on BioCryst's strategic shift to a business development-driven model, particularly following the acquisition of Astria and

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 08:39
Source
Investing.com Canada
Quartr Direct company coverage

BioCryst Pharmaceuticals (BCRX) Cantor Global Healthcare Conference 2025 Summary

BioCryst Pharmaceuticals (BCRX) provided an update at the Cantor Global Healthcare Conference 2025, highlighting strong growth projections for its drug ORLADEYO, with anticipated sales reaching $580–$600 million this year and potentially $1 billion by the decade's end. The compan

Tone
Positive 81/100
Event
Market update
Published
13 Jul 2026 07:40
Source
Quartr
Quartr Direct company coverage

BioCryst Pharmaceuticals (BCRX) Proxy filing Summary

BioCryst Pharmaceuticals' (BCRX) proxy filing outlines the agenda for its Annual Meeting on June 11, 2026, which includes the election of three directors, ratification of Ernst & Young LLP as auditors, an advisory vote on executive compensation, and approval of an amended Stock I

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jul 2026 07:40
Source
Quartr
Simply Wall Street Direct company coverage

BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In Focus

BioCryst Pharmaceuticals (BCRX) is discontinuing internal discovery programs and closing its Discovery Center of Excellence to refocus R&D efforts. Despite mixed long-term returns, the stock is considered 50.9% undervalued with a fair value of $21.30, largely due to strong revenu

Tone
Positive 64/100
Event
Market update
Published
13 Jul 2026 01:40
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

(BCRX) Movement Within Algorithmic Entry Frameworks

This article from Stock Traders Daily discusses Biocryst Pharmaceuticals Inc. (BCRX) and presents various algorithmic trading strategies. It highlights strong sentiment across all horizons supporting an overweight bias, with no resistance levels identified above the current price

Tone
Positive 73/100
Event
Market update
Published
11 Jul 2026 22:09
Source
Stock Traders Daily
Sahm Direct company coverage

Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?

BioCryst Pharmaceuticals announced it would discontinue its internal drug discovery programs and close its Birmingham Discovery Center by the end of 2026, shifting towards external innovation and partnerships for its rare disease pipeline. This strategic pivot aims to create a mo

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 00:40
Source
Sahm
timothysykes.com Direct company coverage

BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock information for BioCryst Pharmaceuticals Inc. (BCRX), including its current stock price and recent performance. It also indicates that there are currently no analyst ratings or detailed earnings information available for the company. The page is part

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 00:11
Source
timothysykes.com
TradingView Direct company coverage

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?

Shares of Penguin Solutions Inc. (PENG), Arista Networks Inc. (ANET), and Biocryst Pharmaceuticals Inc. (BCRX) reached 52-week highs due to positive catalysts and increased price targets from Wall Street analysts. PENG benefited from increased AI demand and analyst upgrades, ANET

Tone
Positive 75/100
Event
Analyst action
Published
09 Jul 2026 03:39
Source
TradingView
Market source Direct company coverage

BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?

BioCryst Pharmaceuticals (BCRX) shares surged 8.1% due to strong performance of its marketed therapies like Orladeyo and Rapivab, and a promising rare disease-focused pipeline. The company is expected to post favorable quarterly earnings and revenue growth, with positive trends i

Tone
Positive 71/100
Event
Earnings
Published
08 Jul 2026 14:10
Source
Market source
Investing.com Direct company coverage

Biocryst Pharmaceuticals stock hits 52-week high at 10.94 USD

BioCryst Pharmaceuticals (BCRX) stock reached a 52-week high of $10.94, reflecting a 22.01% increase over the last year and strong recent momentum with a 30% year-to-date gain. Despite this, InvestingPro analysis suggests the stock might be overvalued. The company recently report

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 00:10
Source
Investing.com
Investing.com Australia Direct company coverage

Biocryst Pharmaceuticals stock hits 52-week high at 10.94 USD By Investing.com

BioCryst Pharmaceuticals Inc. (BCRX) stock recently hit a new 52-week high of $10.94, marking a 22.01% increase over the last year and strong year-to-date and six-month returns. This surge reflects investor confidence and strategic company advancements, despite a significant Q1 2

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 20:41
Source
Investing.com Australia
Sahm Direct company coverage

BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery, Is The Stock Still Undervalued?

BioCryst Pharmaceuticals (BCRX) is transitioning its research model by concluding internal discovery programs and focusing on externally sourced rare disease projects. Despite a 39.85% decrease in its 5-year total shareholder return, the stock has seen recent gains of 17.0% (30-d

Tone
Positive 61/100
Event
Market update
Published
07 Jul 2026 12:10
Source
Sahm
Finviz Direct company coverage

BCRX - Biocryst Pharmaceuticals Inc Volatility & Greeks

This article provides a comprehensive overview of BioCryst Pharmaceuticals Inc. (BCRX), detailing its recent stock performance, key financial metrics, volatility indicators, and various valuation ratios. It covers aspects from market capitalization and sales to insider ownership

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 23:39
Source
Finviz
Stock Titan Direct company coverage

If You Invested $1,000 in Biocryst Pharmaceuticals Inc (BCRX)

This article examines the historical returns of investing $1,000 in Biocryst Pharmaceuticals Inc (BCRX) over 1, 5, and 10 years, noting a 12.3% total return in the last year and a 235.8% return over ten years. It provides annual performance data for BCRX against the S&P 500 and a

Tone
Positive 66/100
Event
Market update
Published
04 Jul 2026 07:11
Source
Stock Titan
AL.com Direct company coverage

Pharmaceutical company closing Birmingham facility

BioCryst Pharmaceuticals, a North Carolina-based company founded in Birmingham, announced it will close its Birmingham Discovery Center of Excellence facility and discontinue internal discovery programs by the end of the year. The company plans to shift its focus to external rese

Tone
Negative 28/100
Event
Market update
Published
02 Jul 2026 23:43
Source
AL.com
The Manila Times Direct company coverage

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted stock options and restricted stock units (RSUs) to nine newly-hired employees. These grants, totaling 33,950 stock options and 91,750 RSUs, were made on July 1, 2026, as inducements in accordance wit

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
The Manila Times
Sahm Direct company coverage

How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story

BioCryst Pharmaceuticals is discontinuing its internal discovery programs and closing its Birmingham Discovery Center, shifting its focus to externally sourced innovation for its rare disease pipeline. This move redefines the company's investment narrative, emphasizing execution

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 11:12
Source
Sahm